Date: 2016-11-09
Type of information: R&D agreement
Compound: miniature livers from human iPS cells for drug discovery
Company: Takeda Pharmaceutical (Japan) Center for iPS Cell Research and Application, Kyoto University (Japan) Yokohama City University (Japan)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details:
- • On November 9, 2016, the Center for iPS Cell Research and Application, Kyoto University (CiRA), Takeda Pharmaceutical and Yokohama City University announced that they entered the joint research agreement on application of the method to produce miniature livers from human iPS cells to drug discovery. The project aims to create a miniature size of a three-dimensional human organ with vascular structures from human iPS cells by imitating the early process of organ development in the womb. Based on human iPS cell-derived miniature liver generation technology developed at Yokohama City University, this research will focus on developing an innovative system that can recreate the complex phenomena found within patients’ bodies. In this way, it will create brand new drug discovery architecture to investigate new therapeutic drugs for intractable diseases or novel predictive platform for detecting rare adverse events that were previously unforeseen with traditional drug discovery research and so on.
- This project, which is a part of the joint research program called “Takeda-CiRA Joint Program for iPS Cell Applications” (T-CiRA) announced by CiRA and Takeda in April 2015, will be led by Associate Professor Takanori Takebe, Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, as the principal investigator. Being the eighth project for T-CiRA, this will be the first project to be led by a researcher outside of CiRA.
Financial terms:
Latest news:
Is general: Yes
